CD274 and neoplasm: To identify tumor cell mechanisms involved in driving the immune phenotype described above, we used previously published transcriptomic data of anti–PD-L1–treated 344SQ tumors, analyzed during response (week 5) and at the development of resistance (week 7) (17).